Report Summarizes Glioblastomas Study Findings from College of Medicine [Clinical Benefit of Bevacizumab and Irinotecan (Bev Plus Iri) In Patients With Relapsed/refractory Glioblastoma (R/rgbm) and Its Potential Predictors]

Press/Media: Press / Media

Period2023 Mar 8

Media coverage

1

Media coverage

  • TitleReport Summarizes Glioblastomas Study Findings from College of Medicine [Clinical Benefit of Bevacizumab and Irinotecan (Bev Plus Iri) In Patients With Relapsed/refractory Glioblastoma (R/rgbm) and Its Potential Predictors]
    Media name/outletImmunotherapy Daily
    Country/TerritoryUnited States
    Date23/3/8
    URLct.moreover.com/?a=50198502685&p=1gw&v=1&x=luLaU93U0Lu8KoMu1jwBDw
    PersonsHyun Woo Park
View all 1
View less